2,5-Dimethoxy-4-methylphenylcyclopropylamine

DMCPA
Names
Preferred IUPAC name
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropan-1-amine
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C12H17NO2/c1-7-4-12(15-3)9(6-11(7)14-2)8-5-10(8)13/h4,6,8,10H,5,13H2,1-3H3 Y
    Key: HYVPPECPQRBJEQ-UHFFFAOYSA-N Y
  • InChI=1/C12H17NO2/c1-7-4-12(15-3)9(6-11(7)14-2)8-5-10(8)13/h4,6,8,10H,5,13H2,1-3H3
    Key: HYVPPECPQRBJEQ-UHFFFAOYAN
  • O(c1c(cc(OC)c(c1)C2CC2N)C)C
Properties
C12H17NO2
Molar mass 207.273 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

2,5-Dimethoxy-4-methylphenylcyclopropylamine (DMCPA) is a lesser-known psychedelic drug and a substituted amphetamine and phenylcyclopropylamine. DMCPA was first synthesized by Alexander Shulgin. In his book PiHKAL, the dosage range is listed as 15–20 mg and the duration is listed as 4–8 hours.[1] DMCPA produces open-eye visuals, anorexia, and psychedelic dreams.[1] Shulgin gives it a +++ on the Shulgin Rating Scale.[1]

Pharmacology

Very little data exists about the pharmacological properties, metabolism, and toxicity of DMCPA.

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

References

  1. ^ a b c DMCPA Entry in PiHKAL
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.